The importance of collaborations between patients and industry is obvious in that no treatment or cure will ever be developed without a strong partnership. In order to collaborate effectively, knowledge about the differences of working with industry versus working in industry is critical. Understanding the priorities and motivation for each stakeholder is critical as they may differ. This session will discuss those different advocacy roles, how to identify overlapping goals between industry and rare disease, and how to measure the effectiveness of these collaborations.
Speaker: Alan Gilstrap, Executive Director of Advocacy and Policy, Akcea
Speaker: Sandra Revill Tremulis, Founder and President, The Lipoprotein(a) Foundation
Speaker: Jenna Swan, Manager of Patient Advocacy, Retrophin
Speaker: Chelsey Fix, MPH, Associate Director of Industry and Government Relations, NephCure Kidney International
Day 2, Track 2